Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

OW 2026 15 November 2026

Impact of Cagrilintide 2.4 mg on Cardiometabolic Risk Indicators:a Post-hoc Analysis of REDEFINE 1

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress poster
Amylin
Cagrilintide
PHASE 3 (RCT)